Head-to-head · free

TScan Therapeutics, Inc. vs First Tracks Biotherapeutics Inc

TCRX vs TRAX — return on capital, cash generation, margins and balance sheet side by side.

TCRX

0 / 2

measures where TCRX leads

TRAX

2 / 2

measures where TRAX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTCRX · FY2025TRAX
Revenue$10.3M—
Net income(129.8M)—
Revenue growth (yearly, multi-year)0.5%—
Free cash flow(139.7M)—
Free cash flow margin-1353.3%—
Net cash / (debt)——
ROIC——
Return on equity-71.3%-40.9%
Gross margin——
Operating margin-1315.4%—
Net debt / EBITDA0.90x0.69x

Figures are as reported by each company; latest fiscal year shown.

Where TScan Therapeutics, Inc.'s cash went (FY2025)

Capital spending
$4.4M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TCRX profile →

Where First Tracks Biotherapeutics Inc's cash went

Not reported yet.

Full TRAX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons